FASEB SRC on Lysophospholipd Mediators in Health and Disease

FASEB SRC 关于健康和疾病中的溶血磷脂介质

• 批准号: 8203973
• 负责人: JULIE D SABA
• 金额: $ 0.4万
• 依托单位: FEDERATION OF AMER SOC FOR EXPER BIOLOGY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-12 至 2012-08-11
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8203973
• 关键词: Address; Affinity; American; Apoptosis; Area; Autophagocytosis; Basic Science; Biochemistry; Biological Markers; Biological Models; Biology; Blood Circulation; Blood Vessels; Brain; Breast; Calcium Signaling; Cardiovascular Diseases; Catabolism; Cell Cycle Progression; Cell Surface Receptors; Cell Survival; Cellular Stress Response; Cellular biology; Chemotaxis; Clinical Research; Clinical Trials; Collaborations; Colon; Colon Carcinoma; Communicable Diseases; Complement; Complex; Cytoskeletal Modeling; DNA Damage; Development; Developmental Process; Disease; Drug resistance; Enzymes; Epigenetic Process; Event; Family; Family member; Functional disorder; G-Protein-Coupled Receptors; Gene Proteins; Genes; Genetic Transcription; Gonadal structure; Growth; Health; Hematologic Neoplasms; Hematopoietic stem cells; Histone Acetylation; Human; Immunology; Industry; Infection; Inflammation; Injury; International; Italy; Lipids; Lung diseases; Lymphocyte; Lysophosphatidic Acid Receptors; Lysophospholipids; Malignant Neoplasms; Malignant neoplasm of ovary; Mediating; Mediator of activation protein; Membrane; Metabolism; Multiple Sclerosis; Natural Killer Cells; Neurology; Nuclear; Oncogenes; Oral; Ovarian; Pathway interactions; Pharmacology; Phospholipids; Physiological; Physiological Processes; Physiology; Play; Prostate; Radiation Injuries; Radiation Tolerance; Reagent; Receptor Gene; Receptor Signaling; Regulation; Research; Research Personnel; Resort; Role; SPHK1 enzyme; Scientist; Signal Transduction; Signaling Molecule; Societies; Sphingolipids; Staging; Thyroid Gland; Tissues; Training; Transcriptional Regulation; Translational Research; Tumor Angiogenesis; Underrepresented Minority; Woman; angiogenesis; autocrine; biological adaptation to stress; cancer cell; cancer type; carcinogenesis; career; drug sensitivity; human disease; lysophosphatidic acid; malignant ascites; malignant breast neoplasm; meetings; migration; novel; novel therapeutics; paracrine; posters; prognostic; programs; radiation resistance; receptor; response; sphingosine 1-phosphate; sphingosine kinase; symposium; therapeutic target; trafficking; tumor progression

DESCRIPTION (provided by applicant): The 6th FASEB Summer Research Conference on "Lysophospholipid Mediators in Health and Disease" will be held August 14-19, 2011 in Lucca, Italy. This conference will address current concepts in the rapidly developing field of lysphospholipid-mediated signaling and related biology. The lysophospholipids sphingosine- 1-phosphate (S1P) and lysophosphatidic acid (LPA) are bioactive lipids generated via catabolism of membrane sphingolipids (S1P) and phospholipids (LPA). They signal through a family of ubiquitously expressed cell surface receptors, formerly called the Endothelial Differentiation Gene (EDG) receptors. Lysophospholipids mediate a plethora of physiological and pathological activities via interactions with their high-affinity G protein- coupled receptors, as well as through recently revealed receptor-independent intracellular mechanisms. LPA and S1P regulate chemotaxis, stress responses, cytoskeletal organization, calcium signaling, cell survival, apoptosis, autophagy, and gene transcription. Lysophospholipid signaling events also contribute to complex physiological and developmental processes including angiogenesis, lymphocyte trafficking and the migration of hematopoietic stem cells, natural killer cells, and cancer cells. Importantly, lysophospholipids play critical roles in carcinogenesis and cancer progression. Enzymes responsible for catalyzing S1P and LPA formation including autotaxin (the principal enzyme responsible for generating LPA) and sphingosine kinase 1 (which generates S1P) are bona fide oncogenes that promote transformation in model systems, are aberrantly expressed in many human cancers, and serve as biomarkers of prognostic significance. Alterations in lysophospholipid metabolism and signaling also contribute to drug and radiation resistance, tumor angiogenesis, and progression of many cancer types including ovarian, breast, prostate, thyroid, colon, brain and hematological malignancies. Further, recent studies indicate that S1P is a nuclear regulator of epigenetic transcriptional control. Tremendous progress has been made in targeting autotaxin, sphingosine kinase and lysophospholipids themselves as novel therapeutic strategies in cancer. Due to the rapid pace of discovery in this field, this biennial conference is essential to achieving maximal translational potential through cross- pollination of ideas, sharing of new reagents and initiation of collaborations between academic scientists, industry and clinician scientists. Toward that end, our specific aims are to: 1) convene an internationally recognized group of investigators to present and discuss novel findings regarding lysophospholipid metabolism, signaling, regulation, pharmacology and clinical trials; 2) to facilitate participation of early career investigators; 3) to promote participation of women and underrepresented minorities. The program includes oral and poster presentation sessions whose themes cover a range of topics including lysophospholipid biochemistry and signaling, pharmacology, and the role of lysophospholipids in disease. In addition, a new Meet the Experts session will facilitate interactions between early career and established scientists in the field. PUBLIC HEALTH RELEVANCE: This is a proposal to support the convening of the 2011 biannual Federation of American Societies for Experimental Biology Summer Research Conference on Lysophospholipid Mediators in Health and Disease. The meeting will bring together an international group of scientists at all career stages to share the most recent and exciting scientific findings regarding two lipid signaling molecules which share a common family of cell surface receptors through which they modulate cell biology and physiological responses. The effects of lysophospholipid signaling are important in the pathophysiology of cancer, cardiovascular disease, immunology, neurology and infectious disease, and key components of these pathways are being targeted for therapeutic purposes. Women, underrepresented minorities and early stage investigators will play an important role in the conference as speakers, chairs, poster presenters and will have opportunities to interact with others through discussions, Meet the Expert and Meet the Editor sessions.

描述（由申请人提供）：第六届FASEB夏季研究会议“溶血磷脂介质在健康和疾病”将于2011年8月14日至19日在卢卡，意大利。本次会议将解决目前的概念在迅速发展的领域溶血磷脂介导的信号和相关的生物学。溶血磷脂鞘氨醇-1-磷酸（S1 P）和溶血磷脂酸（LPA）是通过膜鞘脂（S1 P）和磷脂（LPA）的catalysis产生的生物活性脂质。它们通过一个广泛表达的细胞表面受体家族（以前称为内皮分化基因（EDG）受体）发出信号。溶血磷脂通过与其高亲和力G蛋白偶联受体的相互作用以及通过最近揭示的受体非依赖性细胞内机制介导过多的生理和病理活性。LPA和S1 P调节趋化性、应激反应、细胞骨架组织、钙信号传导、细胞存活、凋亡、自噬和基因转录。溶血磷脂信号传导事件还有助于复杂的生理和发育过程，包括血管生成、淋巴细胞运输以及造血干细胞、自然杀伤细胞和癌细胞的迁移。重要的是，溶血磷脂在癌症发生和癌症进展中起关键作用。负责催化S1 P和LPA形成的酶，包括自分泌运动因子（负责产生LPA的主要酶）和鞘氨醇激酶1（产生S1 P），是促进模型系统转化的真正癌基因，在许多人类癌症中异常表达，并作为具有预后意义的生物标志物。溶血磷脂代谢和信号传导的改变也有助于药物和辐射抗性、肿瘤血管生成和许多癌症类型的进展，包括卵巢癌、乳腺癌、前列腺癌、甲状腺癌、结肠癌、脑癌和血液恶性肿瘤。此外，最近的研究表明，S1 P是一个核调节表观遗传转录控制。靶向自分泌运动因子、鞘氨醇激酶和溶血磷脂本身作为癌症治疗的新策略已经取得了巨大的进展。由于这一领域的发现速度很快，这个两年一度的会议对于通过思想的交叉授粉，新试剂的共享以及学术科学家，工业和临床科学家之间的合作来实现最大的翻译潜力至关重要。为此，我们的具体目标是：1）召集一个国际公认的研究人员小组，介绍和讨论有关溶血磷脂代谢，信号传导，调节，药理学和临床试验的新发现; 2）促进早期职业研究人员的参与; 3）促进妇女和代表性不足的少数民族的参与。该计划包括口头和海报介绍会议，其主题涵盖了一系列主题，包括溶血磷脂生物化学和信号，药理学，以及溶血磷脂在疾病中的作用。此外，一个新的会见专家会议将促进早期职业和建立在该领域的科学家之间的互动。 公共卫生相关性：这是一项支持召开2011年半年度美国实验生物学协会联合会关于溶血磷脂介体在健康和疾病中的夏季研究会议的提案。该会议将汇集所有职业阶段的国际科学家，分享关于两种脂质信号分子的最新和令人兴奋的科学发现，这两种脂质信号分子共享一个共同的细胞表面受体家族，通过它们调节细胞生物学和生理反应。溶血磷脂信号传导的作用在癌症、心血管疾病、免疫学、神经学和感染性疾病的病理生理学中是重要的，并且这些途径的关键组分被靶向用于治疗目的。妇女、代表性不足的少数群体和早期调查人员将在会议中发挥重要作用，担任发言人、主席、海报展示者，并将有机会通过讨论、会见专家和会见编辑会议与其他人互动。